Trials / Completed
CompletedNCT01194050
An Observational Study of Tarceva (Erlotinib) in Routine Practice For First Line Maintenance Therapy in Patients With Non Small Cell Lung Cancer
Erlotinib (Tarceva) in Routine Clinical Practice for First Line Maintenance Therapy (1LM) in Patients With Advanced Non Small Cell Lung Cancer (NSCLC)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 289 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This observational study will investigate the tolerability and efficacy of Tarceva (erlotinib) in daily clinical practice under routine conditions in patients with locally advanced or metastatic non small cell lung cancer. Data will be collected for approximately 12 months.
Conditions
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2013-07-01
- Completion
- 2013-07-01
- First posted
- 2010-09-02
- Last updated
- 2016-11-02
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01194050. Inclusion in this directory is not an endorsement.